Bioactive-material-programmed CAR-T cell living drug for augmented immunotherapy against tumors
The therapeutic efficacy of chimeric antigen receptor (CAR)-T cell therapy against solid
tumors remains hindered by issues including physical barriers, the immunosuppressive …
tumors remains hindered by issues including physical barriers, the immunosuppressive …